Immutep
- Company typePublic
- Founded2001
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Immutep firmographics
Firmographics- Name
- Immutep
- Legal name
- Immutep Limited
- Website
- https://immutep.com
- Company type
- Public
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Immutep industry classification
Industry- Product category
- Immuno-oncology biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
Keywords
Where Immutep is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices4 records
Markets served
Immutep business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Licensing and Milestone Payments: Immutep receives upfront payments, regulatory milestones, development milestones, and commercial milestone payments from licensing partners. For example, Dr. Reddy's deal includes $20 million upfront and up to $349.5 million in milestones plus royalties.
- Royalty Revenue: Future royalty payments on net sales of licensed products in partner territories, including double-digit royalties from Dr. Reddy's on commercial sales.
- Manufacturing Rights Retention: Immutep retains global manufacturing rights for efti, providing potential for manufacturing revenue if products are approved and commercialized.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Other | No commercial products available for pricing |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels5 records
Immutep product offering
Product offeringCore offering
Immutep develops clinical-stage immunotherapy drug candidates based on LAG-3 (Lymphocyte Activation Gene-3) biology for the treatment of cancer and autoimmune diseases. Its lead asset, eftilagimod alfa (efti), is a soluble LAG-3 protein and MHC Class II agonist administered subcutaneously to activate antigen-presenting cells in oncology indications such as NSCLC, HNSCC, breast cancer, and soft tissue sarcoma. The company also develops IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, and earns revenue by licensing its candidates to pharmaceutical partners while retaining manufacturing rights.
Product overview
Immutep is a late clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune diseases. The company's diversified portfolio harnesses LAG-3's ability to stimulate immune response to fight cancer or modulate it to combat autoimmune diseases. The primary focus centers on two proprietary first-in-class therapeutics: eftilagimod alfa (efti) in oncology and IMP761 in autoimmune diseases. The company has four clinical-stage candidates and one early research-stage candidate. Eftilagimod alfa works as a soluble LAG-3 protein and MHC Class II agonist that uniquely activates antigen-presenting cells, while IMP761 is the world's first LAG-3 agonist antibody for autoimmune diseases. Additional assets include IMP731 (LAG-3 depleting antibody) and LAG525 which has been out-licensed to Novartis.
Differentiator
Problem solved
Functional benefit
Products and services
- Eftilagimod alfa (efti) Eftilagimod alfa (efti) is a first-in-class soluble LAG-3 protein and MHC Class II agonist administered subcutaneously that activates antigen-presenting cells (APCs), stimulating both innate and adaptive immune responses for cancer treatment. It is being evaluated in combination with pembrolizumab and chemotherapy in NSCLC, HNSCC, breast cancer, and soft tissue sarcoma.
- IMP761 IMP761 is a first-in-class LAG-3 agonist antibody for autoimmune diseases that acts upstream on activated T cells to target the root cause of autoimmune diseases and restore immune system balance. Phase I study showed dose-dependent immunosuppressive effects in healthy volunteers.
- IMP731 IMP731 is a LAG-3 depleting antibody that eliminates T cells to combat autoimmune diseases. It has been tested in Phase II in active ulcerative colitis and a Phase I/Ib trial in psoriasis.
- LAG525 (ieramilimab) LAG525 (ieramilimab) is an anti-LAG-3 antibody clinical candidate developed by Immutep and licensed to Novartis, which has full responsibility for continued development and commercialization. Immutep is eligible for development-based milestone payments and royalties on net sales.
Quantifiable outcome
- 51.5% median tumor hyalinization/fibrosis in soft tissue sarcoma patients (exceeding 35% target)
- +3 more outcomes
Companies that use Immutep
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles3 records
Immutep technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Immutep partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Dr. Reddy's LaboratoriescoreExclusive licensing and collaboration agreement for development and commercialization of eftilagimod alfa (efti) across most global markets outside North America, Europe, Japan, and Greater China. Immutep received $20 million upfront and is eligible for up to $349.5 million in regulatory, development, and commercial milestone payments, plus double-digit royalties on future sales. Immutep retains global manufacturing rights.
- MSD (Merck US)coreClinical trial collaboration and supply agreement to evaluate combination of efti with KEYTRUDA (pembrolizumab) in multiple solid tumors including non-small cell lung cancer, head and neck cancer, and ovarian cancer (TACTI-002 trial).
- Merck KGaA (Darmstadt, Germany)minorClinical trial collaboration and supply agreement for combination therapies in oncology.
- NovartiscoreLicense agreement for LAG525 (ieramilimab), an anti-LAG-3 antibody. Novartis has full responsibility for continued development and commercialization. Immutep eligible for development-based milestone payments and royalties on sales. Two patent families co-owned with Novartis.
- EOC PharmacoreLicense agreement for eftilagimod alfa in Greater China (Hong Kong, Macau, Taiwan). EOC Pharma is an oncology-focused affiliate of Eddingpharm. Immutep received milestone payment and will receive royalties on net sales.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Immutep competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Immutep social profiles
Digital presenceImmutep compliance and trust
Trust signalCompliance3 records
Immutep financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immutep leadership team
Management profileNumber of profiles
Profiles17 records
Immutep subsidiaries and ownership
Company hierarchySubsidiaries3 records
Immutep funding detail
Funding detailFunding overview
Funding rounds5 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immutep M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immutep
What does Immutep do?
Immutep develops clinical-stage immunotherapy drug candidates based on LAG-3 (Lymphocyte Activation Gene-3) biology for the treatment of cancer and autoimmune diseases. Its lead asset, eftilagimod alfa (efti), is a soluble LAG-3 protein and MHC Class II agonist administered subcutaneously to activate antigen-presenting cells in oncology indications such as NSCLC, HNSCC, breast cancer, and soft tissue sarcoma. The company also develops IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases, and earns revenue by licensing its candidates to pharmaceutical partners while retaining manufacturing rights.
Is Immutep a public or private company?
Immutep is a public company. It is classified as public and is currently operating.
When was Immutep founded?
Immutep was founded in 2001. It employs 11 to 50 people.
Where is Immutep based?
Immutep is headquartered in Sydney, Australia, in the Oceania region.
How does Immutep make money?
Three revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are royalty Revenue and manufacturing Rights Retention.
Does Immutep have an API?
No public API is recorded for Immutep.
What industry is Immutep in?
Immutep's product category is Immuno-oncology biotechnology. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.